Ogbe, A;
Pace, M;
Bittaye, M;
Tipoe, T;
Adele, S;
Alagaratnam, J;
Aley, PK;
... Frater, J; + view all
(2022)
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.
JCI Insight
, 7
(7)
, Article e157031. 10.1172/jci.insight.157031.
Preview |
PDF
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.pdf - Published Version Download (1MB) | Preview |
Abstract
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
| Type: | Article |
|---|---|
| Title: | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1172/jci.insight.157031 |
| Publisher version: | https://doi.org/10.1172/jci.insight.157031 |
| Language: | English |
| Additional information: | Copyright: © 2022, Ogbe et al. This is an open access article published under the terms of the Creative CommonsAttribution 4.0 International License. |
| Keywords: | AIDS/HIV, Adaptive immunity, COVID-19, Cellular immune response, T cells, COVID-19, ChAdOx1 nCoV-19, HIV Infections, Humans, Male, SARS-CoV-2, Vaccination |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10184137 |
Archive Staff Only
 |
View Item |
